Clinical trials: Esrd
Dyslipidemia
Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers
To analyze efficacy of fluvastatin on patients with chronic renal disease by analyzing certain inflammatory markers. In addition, tolerability and safety will also be evaluated in a Spanish population.
- Trial name
- NCT00171262
- Testing
- Fluvastatin
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Novartis
Diabetic Kidney Disease (DKD)
Rubix LS Diabetic Kidney Disease (DKD) Registry Study
Diabetic kidney disease (DKD) is a common complication of type 2 diabetes that can lead to kidney failure and increases the risk of cardiovascular disease.
- Trial name
- NCT07348718
- Testing
- Kidney-Protective Therapies Used in Routine Care
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Rubix LS
Chronic Kidney Failure
Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line
The primary objective is to collect data to evaluate the biocompatibility of two types of blood circuit, already on the market.
- Trial name
- NCT00804453
- Testing
- Cartridge blood set, Standard blood line
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Vantive Health LLC
End-Stage Renal Disease, End-Stage Kidney Disease
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an…
- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Trial name
- NCT05027074
- Testing
- MK-2060
- Where
- 120 sites in United States, Argentina and 13 more
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Arterial Hypertension, Chronic Kidney Disease
PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of Russia
This study is a multi-centre, non-interventional, observational, prospective study with retrospective analysis. The main purpose of the study is to describe the rate of CKD diagnosis in patients with AH and CKD markers.
- Trial name
- PRIORITY-CKD (NCT06372431)
- Where
- 30 sites in Russia
- Volunteers
- 9,914 people
- Sponsor
- AstraZeneca
End Stage Renal Disease, End Stage Renal Failure on Dialysis
First-in-Human (FIH) Study of the Xeltis Hemodialysis Access Graft
A feasibility study is to assess the preliminary safety and performance of the Xeltis hemodialysis access (aXess) graft.
- Trial name
- aXess-FIH (NCT04898153)
- Testing
- aXess
- Where
- 6 sites in Belgium, Italy and 2 more
- Volunteers
- 20 people
- Sponsor
- Xeltis
Anemia Associated With End Stage Renal Disease
Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants
The purpose of this study is to assess the safety and effectiveness of roxadustat dosing regimens among hemodialysis participants converted from erythropoiesis stimulating agent (ESA) therapy or who are ESA-naïve.
- Trial name
- ASPEN (NCT04484857)
- Testing
- Roxadustat
- Where
- 26 sites in United States
- Volunteers
- 283 people
- Sponsor
- Kyntra Bio
Chronic Kidney Disease and Systemic Inflammation
A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation
This study is conducted to see how the ziltivekimab works in the body of Chinese people with chronic kidney disease and systemic inflammation.
- Trial name
- NCT05379829
- Testing
- Ziltivekimab
- Where
- 7 sites in China
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Kidney Failure, Chronic
Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands
This observational study will evaluate the clinical benefit of Zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands.
- Trial name
- NCT01273597
- Where
- 11 sites in Hungary
- Volunteers
- 60 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Kidney Diseases, Kidney Injury
A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants
Part I (bioequivalence) will evaluate the bioequivalence of the Oversea Manufactured Sample (used in the MediBeacon Phase 3 Study 100-103; NCT05425719) and Domestic Manufactured Sample in Single Intravenous Dose of MB-102…
- Conditions
- Kidney Diseases, Kidney Injury, Kidney Failure
- Trial name
- NCT05943977
- Testing
- MB-102 DMID, MB-102 OMID, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- Where
- 2 sites in China
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Anemia
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
The purpose of this study is to evaluate whether hemodialysis patients on peginesatide can be converted to epoetin alfa by using a predefined conversion table while achieving a stable hemoglobin.
- Trial name
- NCT01737879
- Testing
- Peginesatide, Epoetin alfa
- Where
- 23 sites in United States
- Volunteers
- 41 people
- Sponsor
- Amgen
Healthy Volunteers, Chronic Kidney Disease
A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease
The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease.
- Trial name
- NCT07231679
- Testing
- IGT-303
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Ingenia Therapeutics INC
Chronic Renal Failure, Chronic Kidney Disease
Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis
The purpose of this study is to evaluate the safety,efficacy， pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of EPO-018B in participants with chronic kidney disease (CKD) Who are not on dialysis
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- NCT02403362
- Testing
- EPO-018B
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
End-Stage Renal Disease, Hemodialysis
Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease
There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered approximately 1 to 2 hours following hemodialysis.
- Trial name
- NCT01710020
- Testing
- CP-690,550
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Pfizer
Kidney Disease, Chronic
Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic kidney disease under real-world use.
- Trial name
- NCT06527846
- Testing
- JARDIANCE®
- Where
- Japan
- Volunteers
- 1,024 people
- Sponsor
- Boehringer Ingelheim
Kidney Disease
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia
The purpose of this study is to characterize the safety and efficacy of repeat doses of compound 1278863A in subjects with anemia.
- Trial name
- NCT01047397
- Testing
- 1278863A
- Where
- 37 sites in Australia, India and 2 more
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease, Hyperphosphatemia
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a…
- Trial name
- NCT00416520
- Testing
- MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®), Another phosphate binder (Sevelamer)
- Where
- 68 sites in Australia, Austria and 9 more
- Volunteers
- 336 people
- Sponsor
- Tanabe Pharma Corporation
End Stage Renal Disease
Study in End Stage Renal Disease (ESRD) Patients on Hemodialysis to Determine Non-inferiority of the Theranova Dialyzer Compared to the FX80 Dialyzer
In China, the estimated prevalence of patients with ESRD receiving peritoneal dialysis (PD) or maintenance hemodialysis (HD) increased from 51.7 per million population (pmp) at the end of 2007 to 79.1 pmp at the end of 2008.
- Trial name
- NCT03547323
- Testing
- Theranova 400 Dialyzer, FX80 Dialyzer
- Where
- 4 sites in China
- Volunteers
- 156 people
- Sponsor
- Vantive Health LLC
End Stage Renal Disease
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
A U.S. multi-centre post approval registry to analyse the CRBSI rate in patients with the NexSite HD Catheter for long term vascular access for hemodialysis.
- Trial name
- NCT02453646
- Testing
- NexSite HD Patients
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Marvao Medical
End Stage Renal Disease
Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects
This study will assess the pharmacokinetics, safety and tolerability of aliskiren in healthy subjects and patients with End Stage Renal Disease on hemodialysis.
- Trial name
- NCT01568775
- Testing
- Aliskiren
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.